Literature DB >> 32049330

Tuning T helper cell differentiation by ITK.

Jessica P Elmore1, Michael C McGee2, Natalie F Nidetz2, Orchi Anannya1, Weishan Huang1,2, Avery August1.   

Abstract

CD4+ effector T cells effectuate T cell immune responses, producing cytokines to orchestrate the nature and type of immune responses. The non-receptor tyrosine kinase IL-2 inducible T cell kinase (ITK), a mediator of T cell Receptor signaling, plays a critical role in tuning the development of these effector cells. In this review we discussed the role that signals downstream of ITK, including the Ras/MAPK pathway, play in differentially controlling the differentiation of TH17, Foxp3+ T regulatory (Treg) cells, and Type 1 regulatory T (Tr1) cells, supporting a model of ITK signals controlling a decision point in the effector T cell differentiation process.
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  Itk; T-cells; cytokines; kinase; signaling

Year:  2020        PMID: 32049330     DOI: 10.1042/BST20190486

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  7 in total

1.  SHP2 Targets ITK Downstream of PD-1 to Inhibit T Cell Function.

Authors:  Marianne Strazza; Kieran Adam; Shalom Lerrer; Johanna Straube; Sabina Sandigursky; Beatrix Ueberheide; Adam Mor
Journal:  Inflammation       Date:  2021-02-24       Impact factor: 4.657

2.  Targeting SLP76:ITK interaction separates GVHD from GVL in allo-HSCT.

Authors:  Mahinbanu Mammadli; Weishan Huang; Rebecca Harris; Hui Xiong; Samuel Weeks; Adriana May; Teresa Gentile; Jessica Henty-Ridilla; Adam T Waickman; Avery August; Alaji Bah; Mobin Karimi
Journal:  iScience       Date:  2021-03-11

3.  ITK independent development of Th17 responses during hypersensitivity pneumonitis driven lung inflammation.

Authors:  Jessica Elmore; Chavez Carter; Amie Redko; Nicholas Koylass; Amelia Bennett; Max Mead; Marinel Ocasio-Rivera; Weishan Huang; Ankur Singh; Avery August
Journal:  Commun Biol       Date:  2022-02-24

Review 4.  Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia.

Authors:  Yanyan Liu; Yongping Song; Qingsong Yin
Journal:  Front Immunol       Date:  2022-08-19       Impact factor: 8.786

5.  Tissue Treg Secretomes and Transcription Factors Shared With Stem Cells Contribute to a Treg Niche to Maintain Treg-Ness With 80% Innate Immune Pathways, and Functions of Immunosuppression and Tissue Repair.

Authors:  Ruijing Zhang; Keman Xu; Ying Shao; Yu Sun; Jason Saredy; Elizabeth Cutler; Tian Yao; Ming Liu; Lu Liu; Charles Drummer Iv; Yifan Lu; Fatma Saaoud; Dong Ni; Jirong Wang; Yafeng Li; Rongshan Li; Xiaohua Jiang; Hong Wang; Xiaofeng Yang
Journal:  Front Immunol       Date:  2021-02-05       Impact factor: 7.561

6.  TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia.

Authors:  Maria Cristina Puzzolo; Ilaria Del Giudice; Nadia Peragine; Paola Mariglia; Maria Stefania De Propris; Luca Vincenzo Cappelli; Livio Trentin; Gianluigi Reda; Antonio Cuneo; Stefano Molica; Alfonso Piciocchi; Valentina Arena; Francesca Romana Mauro; Anna Guarini; Robin Foà
Journal:  Front Oncol       Date:  2021-04-15       Impact factor: 6.244

Review 7.  Targeting ITK signaling for T cell-mediated diseases.

Authors:  Samuel Weeks; Rebecca Harris; Mobin Karimi
Journal:  iScience       Date:  2021-07-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.